美国华人生物医药科技协会(CBA)第23届年会将于6月9日在马州盖城的MedImmune召开

方小喵

方小喵

记者 at 华府华语
社区记者,负责华府社区新闻
方小喵

        美国华人生物医药科技协会(Chinese Biopharmaceutical Association,简称CBA-USA)第23届年会经过近一年的精心策划多方联络将于6月9日在在AstraZeneca/MedImmune

位于马州盖城的北美总部隆重举行。CBA年会是了解当前生物科技医药发展动态,会见当地生物企业和研究机构顶尖人物,开展业务拓展的极佳机会。本次年会的主题是“创新,创业,创机遇,迎接全球生物制药新时代”。届时,来自全球科研界、工业界、医疗界的杰出代表将展示当前生物研究前沿,结合尖端技术与技术产业化为宗旨,共同推动中美乃至全球生命医学领域的创新发展。

          免疫肿瘤界大牛耶鲁大学教授陈列平博士, Sonofi 全球研发资深副总裁刘勇军博士, Richard Pazdur 博士(Director of OCE, FDA),  Laurence JN Cooper 博士( CEO, Ziopharm) 齐聚一堂,中美医药界大拿们分享过去一年行业飞速进展,同时还有十余家生物医药公司现场招聘。

在此,我们真诚地邀请您出席本次年会,期待与您一起见证生物生命医学领域的一大盛事!注册网址:http://Goo.gl/gaeEDr

年会主讲人介绍:

Wanjun Chen, M.D.               

Senior Investigator

Chief, Mucosal Immunology Section

NIDCR, NIH

Bethesda, MD, USA

陈万军 医学博士

资深研究员

美国国立卫生研究院口腔及头面部研究所粘膜免疫学室主任

 

陈博士是 NIDCR 的终身资深调查员和粘膜免疫学科主任。陈博士是国际公认的免疫学家。他的研究重点是阐明 T 细胞免疫和耐受的机制, 并在动物模型中操纵 T细胞免疫与耐受, 以了解免疫、癌症和传染性疾病的发病机制和免疫治疗。在他对生物医学研究的许多科学贡献中, 陈博士是第一个发现 TGF β诱导 Foxp3 基因的 CD4+ T 细胞和转换成调节 T 细胞 (iTregs)。这一发现改变了人们对 Tregs 的看法, 并被 NIH的内部主任Michael. Gottesman 博士在 NIH主任研讨会中介绍为 “革命性的发现”。描述这一发现的论文已经被引用了4000多次, 并被列为50篇发表在《 J. Exp. Med. 》上论文引用的第三名。为了验证从基本机制研究获得的这些知识, 陈博士发现了一种在体内诱导 autoantigen 特定调控 T 细胞的方法 -这些动物在自身免疫的实验模型 (包括 EAE) 中被发展成I 型糖尿病和类风湿关节炎的疾病。这些体内诱导的抗原特异性 Tregs 抑制靶 autoantigen 特异性炎症免疫细胞而不损害对感染病原体的免疫应答。这一发现为人类自身免疫性疾病和癌症的免疫治疗开辟了一条途径。这一发现被科学评论, 包括新华社 (新华网) 在内的几家通讯社报道。最近, 陈博士发现 d-甘露糖诱导调节 T 细胞的产生, 并抑制自身免疫性糖尿病和哮喘肺炎症。陈博士在国际知名期刊上发表了100多篇同行评议文章, 包括自然、自然医学、自然免疫学、免疫、药物治疗、 科学、转化医学、 细胞、干细胞等, 并应邀在世界许多国际会议和大学发言。陈博士获得了许多荣誉和奖项, 包括美国国立卫生研究院亚洲和太平洋岛民组织的科学成就奖和王迎莱纪念讲师。陈博士已被邀请成为20多家著名的国际科学期刊和美国、欧洲和中国的科学基金会的审稿人。陈博士组织并主持了许多国际会议, 如奠基石讨论会。除了他的科学活动之外, 陈博士还于2015年在美国 (SCBA) 华盛顿-巴尔的摩分会当选中了中国生物学家学会会长。

 

Dr. Chen is a tenured Senior Investigator and the Chief of Mucosal Immunology Section, at NIDCR, NIH. Dr. Chen is an internationally recognized immunologist. His research focuses on elucidating mechanisms of T-cell immunity and tolerance and manipulating T-cell immunity versus tolerance in animal models to understand the pathogenesis of and develop immunotherapy for autoimmunity, cancer and infectious diseases. Among his many scientific contributions to biomedical research, Dr. Chen is the first who discovered that TGF-beta induces Foxp3 gene in naive CD4+ T cells and converts them into regulatory T cells (iTregs). This finding has changed the way people thought of Tregs and was praised by NIH Intramural Director Dr. Michael Gottesman as “ revolution” on his introduction to Dr. Chen as an invited speaker at the NIH Director’s Seminar Series. The paper describing this finding has been cited for more than 4000 times and ranked as the 3rd of 50 most cited papers published on J. Exp. Med. To translate the knowledge acquired from the basic mechanism studies, Dr. Chen has discovered a way to induce autoantigen-specific regulatory T cells in vivo after the animals were developed diseases in experimental models of autoimmunity including EAE, Type I diabetes and rheumatoid arthritis. These in vivo induced antigen-specific Tregs suppressed target autoantigen-specific inflammatory immune cells without compromising the immune responses to infectious pathogens. This finding has opened a way to develop immunotherapy for human autoimmune diseases and cancer. The discovery has been commented by Science and covered by several news agencies including Xinhua News(新华网). Most recently, Dr. Chen has discovered that D-mannose induces generation of regulatory T cells and suppresses autoimmune diabetes and asthmatic lung inflammation. Dr. Chen has published more than 100 peer-reviewed articles in internationally prestigious journals including Nature, Nature Medicine, Nature Immunology, Immunity, J. Exp. Med., PNAS, Science Translational Medicine, Cell, Stem Cell etc., and been invited to speak at many international meetings and universities in the world. Dr. Chen received many honors and awards, including the Scientific Achievement Award from the NIH Asian and Pacific Islander American Organization and the Wang Ying-Lai Memorial Lecturer. Dr. Chen has been invited to be reviewer for more than 20 prestigious international scientific journals and for science foundations in USA, Europe, and China. Dr. Chen has organized and chaired many international meetings such as Keystone Symposia. In addition to his scientific activities, Dr. Chen was also the elected president of the Society of Chinese Biologists at America (SCBA) Washington-DC-Baltimore Chapter in 2015.

Sean Khozin, M.D, MPH

Associate Director, OCE, FDA

Sean Khozin博士是FDA肿瘤学卓越中心的代理副主任,他是信息交换和数据转换(INFORMED)的创始主任,这是一个协作监管科学研究的孵化器,专注于支持创新以加强FDA的使命-宣传并保护公众健康。 INFORMED正在扩增大数据分析的组织和技术基础设施,并检验证据生成中利用现代方法以支持监管决策。 此前,Dr. Khozin在纽约市私人执业,曼哈顿圣文森特医院的主治医师,以及一位专门从事医疗信息技术系统建设的企业家.该医疗信息系统具有虚拟病人管理和现场护理数据可视化和分析功能。 Khozin 荣获2017年Charles A. Sanders生命科学奖(代表FDA接受),2017年FDA关于纳洛酮应用挑战的专员团体奖以及2004年Abraham Lilienfeld生物统计和先进分析奖。

Dr. Sean Khozin is acting associate director at the FDA’s Oncology Center of Excellence, and he is the founding director of Information Exchange and Data Transformation (INFORMED), an incubator for collaborative regulatory science research focused on supporting innovations that enhance the agency’s mission to promote and protect public health. INFORMED is expanding organizational and technical infrastructure for big data analytics and examining modern approaches in evidence generation to support regulatory decisions.

Previously, Khozin was in private practice in New York City, an attending physician at St. Vincent’s Hospital in Manhattan and an entrepreneur specializing in building health information technology systems with virtual patient management and point-of-care data visualization and analytics capabilities.  Khozin received the 2017 Charles A. Sanders Life Sciences Award (accepted on behalf of the FDA), the 2017 FDA Commissioner’s Group Award for the Naloxone App Challenge, and the 2004 Abraham Lilienfeld Award in biostatistics and advanced analytics.

 

Dr. Gang Wang 王刚博士

王刚博士是前CFDA药物审评中心(CDE)首席科学家,主要负责建立、实施和完善与CDE药品审评相关的合规和检查方面的工作。在加入CDE之前,王刚博士在美国FDA工作12年,先后任药品审评和研究中心(CDER)合规办公室生产质量办公室(OMQ)资深政策顾问,主要负责与政策、法规、合规、国际事务及与FDA相关部门之间的协调与合作等事务;FDA驻中国办公室助理主任,主要负责与药品和生物制品有关的政策分析、及美中两国药监部门之间的合作与交流等方面的工作;生物制品审评和研究中心 (CBER)合规及生物制品质量办公室(OCBQ)资深审评员、GMP主持检查员和专家级生物学家,主要负责审评生物制品新药申报和补充材料申报中与CMC和GMP有关的内容,并负责对美国国内和国际生物制药生产厂家生产执照批准前和申报批准前的GMP认证和检查。王刚博士是一位经专业同行评审认定的生物制药生产和GMP认证领域的专家,尤其对细胞和基因治疗药物的审评、生产、GMP认证和监管等领域。王刚博士毕业于南京化学生物系生物化学专业,并获得美国达特茅斯医学院(Dartmouth Medical School)药理学和毒理学专业博士学位。博士毕业后,在美国国家卫生研究院(NIH)国家癌症研究所(NCI)从事博士后研究,主要专注于肿瘤和癌症的细胞及免疫疗法领域的研究。在加入美国FDA之前,王刚博士曾就职于美国得克萨斯州州立大学安德森癌症中心(The University of Texas MD Anderson Cancer Center),任助理教授和课题负责人。

Dr. Gang Wang is former Chief Scientist in the Center for Drug Evaluation (CDE) at China FDA (CFDA). At this position, he is primarily responsible for developing, establishing and implementing the compliance and inspection program in CDE. Prior to joining CDE, Dr. Wang worked at the US FDA for 12 years. More recently, he served as Senior Policy Advisor in the Office of Manufacturing Quality (OMQ), Office of Compliance in CDER. He provides advice on policy, regulation, compliance and international affairs related issues to the senior management in the Office; Assistant Country Director of the FDA China Office in the US Embassy Beijing, responsible for policy analysis, outreach and capacity building in the drug portfolio, and collaboration between US FDA, CFDA, pharmaceutical industry and other stakeholders; Senior Reviewer/Expert Biologist/Lead Inspector of the Office of Compliance and Biologics Quality (OCBQ) in CBER, responsible for CMC reviews and pre-license and pre-approval inspections for biologics regulated by CBER. Dr. Wang is a peer-reviewed expert in biologics manufacturing and CGMP, especially in the area of cell and gene therapy product manufacturing, regulation and supervision. Dr. Wang is a graduate of Nanjing University majoring in biochemistry. He received his Ph.D. in pharmacology and toxicology from Dartmouth Medical School. He conducted his postdoctoral research in immunotherapy of cancer in Dr. Steve Rosenberg’s lab at the National Cancer Institute (NCI). Prior to joining the US FDA, Dr. Wang was an Assistant Professor and Principal Investigator in the Department of Melanoma Oncology at The University of Texas MD Anderson Cancer Center.

Bing Yao Ph.D. 姚正彬博士

姚正彬博士是维拉生物(Viela Bio) 首席执行官。Viela Bio是由AstraZeneca / MedImmune拆分出来。 Viela Bio正在开发针对严重自身免疫性疾病的药物着重针对于导致疾病根源的关键途径。姚博士在生物制药行业已经有二十多年,在多种生物治疗领域有着成功发现和开发的领先经验。在加入Viela Bio之前,他是MedImmune的高级副总裁,分管炎症,自身免疫iMED呼吸。在MedImmune任职期间,他分别在自身免疫,呼吸和免疫肿瘤疾病开发和批准三种新型生物药方面发挥了重要的领导作用。 姚博士还是阿斯利康肿瘤免疫治疗部门的高级副总裁。  在MedImmune之前,他在Genentech,Aventis,Tanox和Amgen担任多个职位,并肩负着越来越多的责任。 姚博士也是NexImmune的董事会成员。 他获得来自爱荷华大学的微生物学和免疫学的博士学位。

Dr. Bing Yao is the CEO of Viela Bio. Inc, a new spin-out from AstraZeneca/MedImmune. Viela Bio is developing medicines for severe autoimmune diseases by targeting critical pathways that are the root cause of disease. Bing has spent more than two decades in the biopharmaceutical industry, has a track record of leading successful discovery and development of multiple biotherapeutics. Prior to Viela Bio, Dr. Yao was Senior Vice President, Head of Respiratory, Inflammation, Autoimmune iMED, MedImmune. During his tenure at MedImmune, he played key leadership roles in the development and approval of three novel biologics for autoimmune, respiratory, and immune-oncology diseases respectively. Dr. Yao was also Senior Vice President, Head of Immuno-Oncology Franchise, AstraZeneca.  

Before MedImmune, Dr. Yao held multiple positions with increasing responsibilities at Genentech, Aventis, Tanox, and Amgen. He is also on the Board of Directors for NexImmune. Dr. Yao received his Ph.D. in Microbiology and Immunology from the University of Iowa.

CBA供稿       许鹏   撰稿

 

Be the first to comment on "美国华人生物医药科技协会(CBA)第23届年会将于6月9日在马州盖城的MedImmune召开"

Leave a comment

Your email address will not be published.




WP Facebook Auto Publish Powered By : XYZScripts.com